Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
PaperCitations, authors & open-access status
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 778 citations, 2013 year and bronze oa status.
778
Citations
2013
Year
bronze
OA Status